REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER
申请人:British Columbia Cancer Agency Branch
公开号:EP2819662B1
公开(公告)日:2019-04-10
US9552457B2
申请人:——
公开号:US9552457B2
公开(公告)日:2017-01-24
[EN] REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER<br/>[FR] REPROGRAMMATION D'INTERACTIONS ENTRE PROTÉINES EFFECTRICES POUR CORRIGER DES DÉFAUTS ÉPIGÉNÉTIQUES DANS LE CANCER
申请人:BRITISH COLUMBIA CANCER AGENCY
公开号:WO2013127011A1
公开(公告)日:2013-09-06
Methods of "reprogramming" epigenetic mark readers or erasers to recognize epigenetic marks other than their cognate (or natural) marks are provided. Reprogramming the reader or eraser can offset the effects of aberrant writer activity (for example, loss of function or overactivity) that can contribute to certain diseases states, such as cancer. The use of the reprogramming compounds identified by these methods in the treatment of such disease states is also provided. Exemplary mark readers that can be targeted by these methods include BPTF and CBX2.
Mobile keto allyl systems. 18. Synthesis and chemistry of N-substituted and N,N-disubstituted 2-benzoyl-1-amino-3-propenes
作者:Norman H. Cromwell、David S. Soriano、Earl Doomes